Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib / II Trial Evaluating the Association Myocet - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum

Trial Profile

Phase Ib / II Trial Evaluating the Association Myocet - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Ovarian cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Gineco; MYCA
  • Most Recent Events

    • 14 Nov 2018 Results published in the Gynecologic Oncology
    • 31 Aug 2018 Biomarkers information updated
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top